[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX360827B - Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina. - Google Patents

Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina.

Info

Publication number
MX360827B
MX360827B MX2015010032A MX2015010032A MX360827B MX 360827 B MX360827 B MX 360827B MX 2015010032 A MX2015010032 A MX 2015010032A MX 2015010032 A MX2015010032 A MX 2015010032A MX 360827 B MX360827 B MX 360827B
Authority
MX
Mexico
Prior art keywords
nash
alcoholic steatohepatitis
methods
treating non
fatty liver
Prior art date
Application number
MX2015010032A
Other languages
English (en)
Inventor
Dohil Ranjan
Schneider Jerry
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360827(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of MX360827B publication Critical patent/MX360827B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción se relaciona, en general, al tratamiento de desórdenes del hígado graso que comprende administrar composiciones que comprenden productos de cisteamina. La descripción proporciona la administración de composiciones de cisteamina entéricamente recubiertas para tratar desórdenes del hígado graso, tal como la enfermedad de hígado graso no alcohólica (NAFLD) y esteatohepatitis no alcohólica (NASH).
MX2015010032A 2007-11-30 2008-11-28 Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina. MX360827B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31
PCT/US2008/085064 WO2009070781A1 (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Publications (1)

Publication Number Publication Date
MX360827B true MX360827B (es) 2018-11-16

Family

ID=40679016

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015010032A MX360827B (es) 2007-11-30 2008-11-28 Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina.
MX2010005921A MX2010005921A (es) 2007-11-30 2008-11-28 Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010005921A MX2010005921A (es) 2007-11-30 2008-11-28 Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina.

Country Status (25)

Country Link
US (5) US7994226B2 (es)
EP (2) EP2214480B1 (es)
JP (3) JP5583022B2 (es)
KR (1) KR20100091219A (es)
CN (2) CN104825430B (es)
AR (1) AR069500A1 (es)
AU (1) AU2008329628B2 (es)
BR (1) BRPI0819690B8 (es)
CA (1) CA2706768C (es)
CL (1) CL2008003582A1 (es)
CY (1) CY1114126T1 (es)
DK (1) DK2214480T3 (es)
ES (1) ES2417179T3 (es)
HR (1) HRP20130590T1 (es)
IL (2) IL205909B (es)
MX (2) MX360827B (es)
MY (1) MY156316A (es)
NZ (1) NZ585732A (es)
PL (1) PL2214480T3 (es)
PT (1) PT2214480E (es)
RU (1) RU2498795C2 (es)
SG (1) SG10201403200RA (es)
TW (2) TWI535435B (es)
WO (1) WO2009070781A1 (es)
ZA (1) ZA201003670B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707277B1 (pt) 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
AU2008329628B2 (en) 2007-11-30 2014-06-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
JP5800368B2 (ja) * 2010-05-19 2015-10-28 興和株式会社 非アルコール性脂肪性肝炎の予防及び／又は治療剤
BR112012031194A2 (pt) * 2010-06-08 2018-05-29 Krisani Biosciences P Ltd derivados de cisteamina e seu uso no tratamento de ehna
US20140187594A1 (en) * 2010-07-28 2014-07-03 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130085075A1 (en) * 2011-06-06 2013-04-04 Meso Scale Technologies, Llc Diagnostic methods for liver disorders
KR101974675B1 (ko) 2011-09-16 2019-05-02 갈렉틴 테라퓨틱스, 인크. 비알콜성 지방간염 및 비알콜성 지방간 질환의 치료를 위한 갈락토-람노갈락투로네이트 조성물
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
JP6411215B2 (ja) * 2011-11-22 2018-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
HK1206646A1 (en) * 2012-03-29 2016-01-15 Halo Therapeutics, Llc Dosage forms of halofuginone and methods of use
US9763974B2 (en) 2012-06-06 2017-09-19 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
EP3132795B1 (en) * 2014-04-18 2020-10-21 LG Chem, Ltd. Composition for preventing or treating fatty liver diseases
US20180050078A1 (en) * 2015-03-03 2018-02-22 KOHJIN Life Sciences Co., Ltd. Composition for improving or preventing nonalcoholic fatty liver
TW202247838A (zh) * 2015-07-02 2022-12-16 美商地平線罕見醫學製藥有限責任公司 Ado抗性半胱胺類似物及其用途
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
CN110719780A (zh) * 2017-06-08 2020-01-21 N-基因研究实验室公司 用于治疗nash和用于预防nash诱导的hcc的方法
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
JP7208982B2 (ja) * 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
JP7538541B2 (ja) 2019-03-26 2024-08-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換されたアミノチオール及びアミノジスルフィド化合物、及びそれらの使用
AU2020316017A1 (en) * 2019-07-19 2022-02-17 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2001058708A1 (en) * 2000-02-14 2001-08-16 Len Booysen Stabilizer unit
CN1144585C (zh) 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CN1596111A (zh) 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
CN1635882B (zh) 2002-01-04 2010-11-10 桑得医药品公司 组合物在制备治疗听力丧失的药物中的用途
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
JP4966665B2 (ja) * 2003-11-19 2012-07-04 オメガ バイオ−ファーマ （アイ．ピー．１） リミテッド アルコール代謝を改善し、二日酔いの影響を軽減するための材料と方法
RU2367423C2 (ru) 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
US20050209441A1 (en) * 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
RU2387445C2 (ru) * 2004-05-03 2010-04-27 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Материалы и способы модуляции метаболизма
BRPI0519606A2 (pt) 2005-01-05 2009-02-25 Abdalla Magd Ahmed Kotb sÍntese, produÇço e utilidade da taurina como um remÉdio
CA2605631A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
BRPI0707277B1 (pt) * 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
WO2007121545A1 (en) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
WO2007130636A2 (en) 2006-05-03 2007-11-15 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
US20100028319A1 (en) 2007-02-02 2010-02-04 Kaneka Corporation Composition for prevention or treatment of diabetes
AU2008329628B2 (en) * 2007-11-30 2014-06-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

Also Published As

Publication number Publication date
RU2498795C2 (ru) 2013-11-20
BRPI0819690A2 (pt) 2014-10-07
AU2008329628B2 (en) 2014-06-26
TW200927093A (en) 2009-07-01
EP2636404A2 (en) 2013-09-11
US7994226B2 (en) 2011-08-09
EP2214480B1 (en) 2013-03-27
US20160143865A1 (en) 2016-05-26
JP5583022B2 (ja) 2014-09-03
BRPI0819690B1 (pt) 2019-07-30
EP2214480A4 (en) 2010-09-29
TW201513855A (zh) 2015-04-16
SG10201403200RA (en) 2014-10-30
CA2706768C (en) 2016-06-28
JP6121951B2 (ja) 2017-04-26
BRPI0819690B8 (pt) 2021-05-25
US9149448B2 (en) 2015-10-06
WO2009070781A1 (en) 2009-06-04
US9511038B2 (en) 2016-12-06
HRP20130590T1 (en) 2013-08-31
CL2008003582A1 (es) 2009-04-03
CN101932238A (zh) 2010-12-29
ZA201003670B (en) 2011-08-31
IL254586A0 (en) 2017-11-30
TWI535435B (zh) 2016-06-01
JP2014237670A (ja) 2014-12-18
CN101932238B (zh) 2015-04-08
PT2214480E (pt) 2013-07-23
EP2636404B1 (en) 2019-03-20
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
MX2010005921A (es) 2010-06-11
PL2214480T3 (pl) 2013-11-29
RU2010126631A (ru) 2012-01-10
US8263662B2 (en) 2012-09-11
US20120015005A1 (en) 2012-01-19
KR20100091219A (ko) 2010-08-18
IL205909A0 (en) 2010-11-30
HK1141945A1 (en) 2010-11-26
MY156316A (en) 2016-02-11
EP2636404A3 (en) 2013-10-16
ES2417179T3 (es) 2013-08-06
CY1114126T1 (el) 2016-07-27
AR069500A1 (es) 2010-01-27
US20130183351A1 (en) 2013-07-18
IL205909B (en) 2018-05-31
DK2214480T3 (da) 2013-07-08
JP2017165735A (ja) 2017-09-21
US10307386B2 (en) 2019-06-04
AU2008329628A1 (en) 2009-06-04
US20170304233A1 (en) 2017-10-26
CA2706768A1 (en) 2009-06-04
EP2214480A1 (en) 2010-08-11
NZ585732A (en) 2012-02-24
JP2011505375A (ja) 2011-02-24
US20100303870A1 (en) 2010-12-02
TWI478710B (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MX2010010954A (es) Farmaco contra cancer de higado.
MX351128B (es) Polipeptidos manipulados que tienen duracion de accion incrementada.
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
IN2015DN00376A (es)
EP4306165A3 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013009539A8 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
TN2009000213A1 (en) Combination
WO2007109583A3 (en) Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2007130501A3 (en) Combination therapy for treatment of cancer
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2019232415A8 (en) Bacteria engineered to treat liver disease
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
WO2020077094A8 (en) Tca cycle intermediates and methods of use thereof
WO2008106606A3 (en) Carotenoid analogs and derivatives in the treatment of prostate cancer